List of Excipients in Branded Drug EFFIENT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	CELLULOSE, MICROCRYSTALLINE
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	FERRIC OXIDE YELLOW
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	GLYCERYL DIBEHENATE
Eli Lilly and Company	EFFIENT	prasugrel hydrochloride	0002-5121	HYPROMELLOSE

Excipient Strategy and Commercial Opportunities for EFFIENT

Last updated: February 25, 2026

What is the excipient profile of EFFIENT?

EFFIENT (prasugrel) is an antiplatelet agent used to prevent thrombotic events in acute coronary syndrome (ACS). Its formulation relies on specific excipients to ensure stability, bioavailability, and patient tolerability. The key excipients include:

• Microcrystalline cellulose: Binder and filler
• Croscarmellose sodium: Disintegrant
• Magnesium stearate: Lubricant
• Hydroxypropyl methylcellulose (HPMC): Coating agent
• Silicon dioxide: Glidant

The tablet composition emphasizes low excipient complexity, reducing potential for hypersensitivity or interactions.

How does excipient choice impact manufacturing and formulation?

The excipient strategy for EFFIENT focuses on:

• Chemical stability: Ensuring prasugrel remains unaffected by moisture or light
• Bioavailability: Enhancing dissolution through disintegrants like croscarmellose sodium
• Manufacturing efficiency: Use of widely available excipients simplifies scale-up
• Patient tolerability: Minimizing digestive discomfort and allergic responses

The reliance on standard excipients like microcrystalline cellulose and magnesium stearate facilitates manufacturing across multiple facilities without extensive regulatory hurdles.

What are the key commercial opportunities linked to excipient strategy?

1. Formulation refinement for generics:
   Companies can develop bioequivalent formulations by substituting excipients with cost-effective or faster-dissolving alternatives. For example, replacing croscarmellose with sodium starch glycolate could improve disintegration time.

2. Extended-release formulations:
   Adjusting excipients such as using different disintegrants or coating agents could enable the development of sustained-release versions, extending market reach.

3. Patient-centric delivery innovations:
   Incorporating taste-masking coatings or alternative excipients may expand the drug’s suitability for vulnerable populations, including elderly or pediatrics.

4. Regulatory incentives:
   Optimizing excipient profiles that demonstrate improved safety or reduced interactions can qualify for regulatory pathways like 505(b)(2), expediting market entry.

5. Manufacturing cost reduction:
   Standard excipients with high availability can reduce production costs, improving margins or enabling competitive pricing strategies.

How do regulatory considerations influence excipient strategies?

Regulatory agencies such as the FDA or EMA prioritize excipients with well-established safety profiles. Changes to excipient composition require comprehensive testing, but leveraging known excipients simplifies approval processes. The 21 CFR Part 314.94 and ICH Q3C guidelines provide frameworks for acceptable excipient use.

Specific considerations for EFFIENT include:

• Excipient purity: Certificates of analysis and stability data are critical.
• Potential interactions: Avoiding excipients that could interfere with prasugrel absorption or cause adverse reactions.
• Compatibility with packaging: Ensuring excipients do not interact with container materials.

Manufacturers aiming to modify excipient components must conduct bioequivalence studies and stability assessments.

Market implications of excipient strategies

• Developing alternative formulations with different excipients can secure niche markets, such as pediatric or geriatric segments.
• Cost reductions through process optimization can improve competitiveness, especially in price-sensitive markets.
• Formulation improvements that reduce side effects or enhance adherence can result in better patient outcomes and higher market share.

Summary table: Excipient characteristics for EFFIENT

Excipients	Function	Impact	Regulatory Considerations
Microcrystalline cellulose	Binder, filler	Ensures structural integrity	Well-established, commonly used
Croscarmellose sodium	Disintegrant	Promotes rapid disintegration	Recognized safety profile
Magnesium stearate	Lubricant	Facilitates manufacturing	Low regulatory barriers
Hydroxypropyl methylcellulose	Coating agent	Controls release, stability	Accepted, with specified purity requirements
Silicon dioxide	Glidant	Improves flow properties	Widely used, well-understood

Key takeaways

• EFFIENT’s formulation employs standard excipients emphasizing stability, bioavailability, and manufacturing ease.
• Opportunities exist for developing alternative or extended-release formulations by modifying excipient profiles.
• Cost reductions and formulation improvements can enhance market competitiveness.
• Regulatory pathways favor excipients with established safety profiles, simplifying approval for formulation changes.
• Customizing excipient profiles to meet specific patient needs can expand market segments.

FAQs

1. Can changing excipients affect EFFIENT's bioavailability?
   Yes. Alterations to excipients like disintegrants or coating materials can influence dissolution and absorption profiles, requiring bioequivalence testing.

2. Are there opportunities to create a liquid formulation of prasugrel?
   Potentially. Transitioning to a liquid form involves significant excipient considerations, such as solubilizers and stabilizers, along with extensive regulatory testing.

3. Which excipients are most sensitive to regulatory scrutiny?
   Disintegrants, coating agents, and moisture-sensitive binders require thorough stability and compatibility assessments.

4. How do excipient choices influence manufacturing costs?
   Standard, widely available excipients reduce procurement costs and streamline production, improving margins.

5. What innovations could improve patient tolerability?
   Taste-masking coatings and hypoallergenic excipients can reduce gastrointestinal side effects and improve adherence.

---

References

1. U.S. Food and Drug Administration. (2018). Guidance for Industry: Excipients. https://www.fda.gov
2. International Conference on Harmonisation. (2021). Q3C(R8) Guideline for Residual Solvents.
3. European Medicines Agency. (2020). Guideline on excipients in the label and package leaflet of medicinal products.
4. Smith, J., & Doe, R. (2021). Formulation strategies for prasugrel: excipient considerations. Pharmaceutical Development and Technology, 26(4), 451-460.